Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H5ClN2O |
Molecular Weight | 168.58 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=CC(Cl)=CC=C2O1
InChI
InChIKey=YGCODSQDUUUKIV-UHFFFAOYSA-N
InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)
Zoxazolamine is a centrally acting muscle relaxant. It decreased striatal dopamine metabolism without affecting striatal dopamine concentrations. More specifically, Zoxazolamine was shown to decrease striatal dopamine turnover without directly affecting dopamine synthesis, catabolism, reuptake, or release. It is the IK(Ca) channel opener. It was approved for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases. Later, it was submitted for the drug's use as a uricosuric agent to treat gout. It was withdrawn from the market due to hepatotoxicity.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0042417 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6467036 |
|||
Target ID: CHEMBL4305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10712246 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Flexin Approved UseZoxazolamine was indicated as a uricosuric agent to treat gout. Launch Date1956 |
|||
Primary | Flexin Approved UseZoxazolamine was indicated for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases Launch Date1956 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13571254/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
ZOXAZOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 4 times / day multiple, oral (starting) Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 40 years n = 1 Health Status: unhealthy Condition: chronic polyartieular gout Age Group: 40 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (acute, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hepatitis | acute, 1 patient Disc. AE |
250 mg 4 times / day multiple, oral (starting) Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 40 years n = 1 Health Status: unhealthy Condition: chronic polyartieular gout Age Group: 40 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides. | 1974 Nov |
|
Effect of benzopyrone derivatives on drug activity and metabolism. | 1986 Oct-Dec |
|
Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. | 2000 Mar |
|
Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo. | 2001 Jan |
|
Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. | 2001 Mar |
|
Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. | 2001 Nov |
|
Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A. | 2002 Dec |
|
Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. | 2003 Jan 3 |
|
Unexpected down-regulation of the hIK1 Ca2+-activated K+ channel by its opener 1-ethyl-2-benzimidazolinone in HaCaT keratinocytes. Inverse effects on cell growth and proliferation. | 2003 Jan 31 |
|
Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression. | 2004 Jul |
|
Effect of some biologically interesting substituted tetrahydro-1,4-oxazines on drug metabolising enzymes and on inflammation. | 2005 Oct |
|
Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice. | 2006 Oct 15 |
|
Hepatoprotective potential of Aloe barbadensis Mill. against carbon tetrachloride induced hepatotoxicity. | 2007 May 22 |
|
Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain. | 2008 Oct |
|
Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. | 2009 Aug |
|
9,9-Dimethyl-12-(4-nitro-phen-yl)-9,10-dihydro-12H-benzo[a]xanthen-11(8H)-one. | 2009 Nov 21 |
|
Bioenhancers: Revolutionary concept to market. | 2010 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14492563
0.5 gm daily dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14648123
Mouse aortic endothelial cells were loaded with 0.5 uM Ca2+ in the pipette and current measured at 50 and −50 mV during repetitive ramps and the corresponding I/V curves constructed. 100 uM of zoxazolamine activated the K(Ca) current.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C921
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D015049
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
24995
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
SUB00192MIG
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
C152966
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
6103
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
m11669
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL472566
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
9DOW362Q29
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
DTXSID1045245
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
524
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
100000078820
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
2876
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
61-80-3
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
Zoxazolamine
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY | |||
|
200-519-4
Created by
admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)